The National Center for Research Resources has funded a new program to support preclinical
and clinical gene therapy efforts. The National Gene Vector Biorepository (NGVB) will
bring a variety of programs online during the next year. One of the resources will
be a continuation of the Pharmacology/Toxicology (Pharm/Tox) Database formerly maintained
by the National Gene Vector Laboratory. The purpose of the database is to provide
gene therapy investigators with a catalog of gene therapy biodistribution and toxicology
studies on file with the US Food and Drug Administration (FDA).
Pharm/tox refers to any in vitro or animal study that seeks to determine the therapeutic
or toxic effect of a drug product (including gene therapy). Pharm/tox studies are
designed to estimate the dose and dosing schedule as well as to identify the potential
toxicity of drug products before they are administered to humans. These studies, which
are required by the FDA, are submitted in an Investigational New Drug (IND) application—the
established mechanism for FDA oversight of investigational drug development. The IND
application must outline what is known about the drug, how the drug will be manufactured,
the clinical protocol under which the drug will be administered, and how the patients
will be informed about potential risks; in addition, it must include the results of
pharm/tox studies.
The type and scope of a pharm/tox study will depend on several factors, including
the product itself, the route of administration, the disease being treated, and the
availability of suitable animal models. Given the complexity of products and disease
indications, a customized pharm/tox plan is usually required. Therefore, investigators
are well advised to draft a detailed pharm/tox plan, then engage the FDA via a Pre-Pre-IND
or Pre-IND meeting before initiating the study, to minimize the chance that the study
will be inadequate or insufficient to support the IND application.
Why is the Pharm/Tox Database needed? There are at least three reasons to provide
a public catalog of pharm/tox studies. First, the results of such studies are generally
not available. Many go unpublished because they are not viewed as hypothesis-driven
research, and studies that support clinical trials generally have no significant findings.
The second need for the database is financial. These studies, especially when done
in nonhuman primates, are expensive and use valuable animal resources. Because the
costs of the studies can exceed the cost of vector production and testing, there is
a financial incentive for academic investigators and the National Institutes of Health
(NIH) to avoid unnecessary duplication of studies. Third, the time needed to admit
new products into clinical trial may be shortened if duplicative pharm/tox studies
are avoided.
How can the database decrease costs? To protect the proprietary information of commercial
sponsors, the FDA is prohibited by law from disclosing or using pharm/tox data submitted
by one investigator for the benefit of another. An exception can be made when the
FDA is given permission by the individual who submitted the original data. This is
done with a “letter of cross-reference” written by the owner of the pharm/tox data.
The letter authorizes the FDA to utilize the data in its deliberation of a specified
IND application. By allowing the FDA to consider studies it has on file, it is hoped
that subsequent gene therapy IND applications will not be viewed in isolation but
can build on existing pharm/tox data and provide more focused (and less expensive)
studies.
Generally, an individual who obtains a letter of cross-reference from a commercial
or academic institution is not shown the primary data contained in the referenced
file. Because it is ultimately the FDA that decides whether existing data can be used
in support of an IND application, not sharing the primary data protects confidentiality
and proprietary information while still accomplishing the goal of permitting the FDA
to reference the data. The NGVB Pharm/Tox database was designed with similar considerations;
primary data are not contained in the database, but detailed information is provided
to investigators so that they can identify studies of relevance to their IND application.
What is contained in the database? It contains information regarding the study design
and methodology, dose level, assessment vector type and manufacturing grade, species
used in animal studies, route of administration, and detailed lists of analyses performed.
For each study there are details on the number of animals evaluated and the dosing,
as well as summary information about the results and implications of the study. The
site and sponsor of the study are also listed.
Who should use the database? Investigators who have not previously submitted a pharm/tox
study to the FDA will find the database an excellent educational resource. The studies
can serve as examples and help identify the scope of work required for previous studies
that had similar routes of administration, vector systems, and/or transgenes. A tutorial
is being developed to provide additional guidance on study design and interacting
with the FDA.
The database should be reviewed by anyone submitting an IND application to determine
whether prior work can be used to decrease the scope (and cost) of the pharm/tox studies.
For example, a review of the database may identify an existing study using a different
transgene but a similar vector, manufacturing methodology, and route of administration.
Although the FDA may require a toxicological assessment of the transgene, it might
allow a limited biodistribution study based on information already on file in another
IND application. The NGVB can facilitate the letter of cross-reference, and it is
the expectation of NIH that letters will be provided to academic investigators for
studies supported with NIH funds. For commercial entities that participate in this
resource, the decision about whether to share this information is at their discretion.
The database can also serve as a resource for grant reviewers and NIH program officers
to determine whether grant applicants are seeking funds for duplicative work.
A list of current and pending studies recorded in the database is provided in
Table 1
. The database search site can be viewed at http://www.ngvl.org/include/tox/index.php,
where short abstracts of the studies can be accessed. Access to the full contents
of the database can be obtained by registering with the NGVB Coordinating Center.
Academic, commercial, or other interested parties are welcome to register and view
the database.
The NGVB also requests that anyone involved with important gene therapy pharm/tox
studies contribute to the database. The Coordinating Center can assist in uploading
the information and will make the process as easy as possible. Contact information
is provided on the NGVB website, https://www.ngvbcc.org.
Finally, over the next year the NGVB will be developing a variety of other support
resources for gene therapy investigators, including a reagents repository, assistance
with vector insertion site assays and analysis, and archiving services for FDA-monitored
samples and products.